Ann: CardieX Appoints New Chinese Distributor to Drive Growth, page-10

I see Team@Onmarket had an announcement today re Cardiex. This maybe the reason for the lift in SP.

Investment exposure to three of the fastest growing global healthcare market opportunitiesHi,You are receiving this email because you have previously shown interest in companies looking to improve the health and well-being of people through health care and technological developments.OnMarket has just partnered with ASX listed company CardieX Limited [ASX:CDX] to assist with their investor communications. CardieX Ltd's current share price is $0.028 and market capitalisation is $20 million. CardieX Ltd. is a global health technology company designing and developing products for the management of cardiovascular diseases. Its XCEL device is the world leader in measuring central blood pressure (cBP), which is considered essential for the management of hypertension and related cardiovascular disorders. Hypertension leads to cardiovascular disease — the #1 killer in the developed world.CardieX Ltd. has operations in medical technologies, wearable devices, and telehealth solutions. They provide digital and device-based solutions for large-scale population health disorders with significant market scale. Their technology is the gold standard in non-invasive central blood pressure, and has FDA clearance in the USA. They recently signed a transformative wearables deal with Mobvio China in September 2019, which represents a major milestone for the company.Here is a short 3 minute video that explains the CardieX business in more detail.CardieX's new CEO Craig Cooper brings potential transformational change to the company, leveraging its core intellectual property with enabling technologies that have emerged in recent years to enter new markets, both clinical and consumer. The CardieX technology is currently available in your doctor’s office — and will be coming soon to home blood pressure monitors and consumer wearables.